These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20424531)

  • 1. [From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
    Rossolini GM
    Infez Med; 2009 Dec; 17 Suppl 5():5-12. PubMed ID: 20424531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of fluoroquinolone use to avoid microbial resistance in clinical practice.
    Peterson LR
    Postgrad Med; 2001 Feb; 109(2 Suppl):51-9. PubMed ID: 19667558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical consequences of antimicrobial resistance.
    Rice LB
    Curr Opin Microbiol; 2009 Oct; 12(5):476-81. PubMed ID: 19716760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibacterial drug resistance in Latin America: consequences for infectious disease control].
    Casellas JM
    Rev Panam Salud Publica; 2011 Dec; 30(6):519-28. PubMed ID: 22358396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals.
    Rogues AM; Dumartin C; Amadéo B; Venier AG; Marty N; Parneix P; Gachie JP
    Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1389-95. PubMed ID: 17994520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases.
    Ishikawa K; Hamasuna R; Uehara S; Yasuda M; Yamamoto S; Hayami H; Takahashi S; Matsumoto T; Minamitani S; Kadota J; Iwata S; Kaku M; Watanabe A; Sunakawa K; Sato J; Hanaki H; Tsukamoto T; Kiyota H; Egawa S; Deguchi T; Matsumoto M; Tanaka K; Arakawa S; Fujisawa M; Kumon H; Kobayashi K; Matsubara A; Wakeda H; Amemoto Y; Onodera S; Goto H; Komeda H; Yamashita M; Takenaka T; Fujimoto Y; Tsugawa M; Takahashi Y; Maeda H; Onishi H; Ishitoya S; Nishimura K; Mitsumori K; Ito T; Togo Y; Nakamura I; Ito N; Kanamaru S; Hirose T; Muranaka T; Yamada D; Ishihara S; Oka H; Inatomi H; Matsui T; Kobuke M; Kunishima Y; Kimura T; Ichikawa T; Kagara I; Matsukawa M; Takahashi K; Mita K; Kato M; Okumura K; Kawanishi H; Hashimura T; Aoyama T; Shigeta M; Koda S; Taguchi K; Matsuda Y
    J Infect Chemother; 2015 Sep; 21(9):623-33. PubMed ID: 26166322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
    Huang X; Bao Y; Zhu S; Zhang X; Lan S; Wang T
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3928-32. PubMed ID: 26238324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
    Van TT; Minejima E; Chiu CA; Butler-Wu SM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
    Prasad SV; Ballal M; Shivananda PG
    Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Chemotherapy; 1986; 32(5):425-30. PubMed ID: 3093154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
    Kobayashi I; Matsuzaki K; Omika K; Hasegawa M; Sato Y
    Jpn J Antibiot; 2007 Apr; 60(2):98-106. PubMed ID: 17612257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.
    McDonald M; Blondeau JM
    J Cataract Refract Surg; 2010 Sep; 36(9):1588-98. PubMed ID: 20692574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Trend in the susceptibility of the most frequent bacterial pathogens isolated at Hospital General La Mancha Centro over 2010-2012 period].
    Asencio MÁ; Huertas M; Carranza R; Franco M; Castellanos J; Barberá JR; Conde Mdel C; Tenías JM
    Rev Esp Quimioter; 2014 Dec; 27(4):261-8. PubMed ID: 25536430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.